Mapqi Medical Secures Tens of Millions in Series B Funding to Advance Neurovascular Intervention Products

VCBeat has learned that Mapuchi Medical (Shenzhen Mapuchi Medical Technology Co., Ltd.), a company specializing in the R&D of interventional guidewires and catheters, recently secured tens of millions of yuan in Series B financing. This round was led by Sanze Venture Capital and Ruifeng Kangqi Investment. Fu Xuesen, Chairman of Mapuchi Medical, stated that the funds will be used to expand its Japanese R&D center and promote its products in both domestic and international markets.

Shenzhen Mapuchi Medical Technology Co., Ltd. was established in 2015. After five years of rigorous research and development, the company has built its product pipeline starting with interventional access devices, forming a series of product lines including hydrophilic-coated guidewires, micro-guidewires, and microcatheters, covering coronary, peripheral, and neurointerventional fields. Currently, four of the company’s guidewire products have obtained NMPA and CE certifications and possess independent intellectual property rights, with more than ten new products scheduled for sequential market launch next year.

Fu Xuesen told us that since its establishment, the company has gone through three important stages. The first stage was the initial R&D phase after founding, during which it made detailed strategic layouts in guidewire products; the second stage occurred in 2018 when it acquired a Japanese R&D center, leading to comprehensive upgrades and optimizations of its product portfolio; the third stage, beginning in 2020, saw the company’s Chinese and Japanese technical teams break through key technological barriers, expanding its offerings from coronary interventions to neurointerventions. In the field of neurointervention, the company has established a series of product lines, including micro-guidewires, microcatheters, and aspiration catheters.

Prior to this financing round, Mapuchi Medical completed its Series A funding in 2018, raising tens of millions of yuan. Two years later, Mapuchi Medical has once again garnered investor interest, with Fu Xuesen attributing this success to the company’s team advantages.

Guidewire products have long been monopolized by foreign companies in China, primarily because the research, development, and manufacturing of guidewires and catheters demand exceptionally high standards in materials science and processing technology. To break through this technical bottleneck, Mapuchi Medical has recruited a team of senior R&D engineers with extensive experience in the interventional industry from both China and Japan. The head of R&D at its Japan center is a highly seasoned engineer within the Japanese industry, boasting decades of experience in interventional product development and having participated in the R&D of products for multiple companies, including Terumo, Asahi Intecc, and Olympus.

“The company’s management team collaborates in a coordinated and efficient manner. Through the joint efforts of the Chinese and Japanese R&D teams, we have overcome critical technical bottlenecks in products such as guidewires and catheters, rapidly advancing the development of various product pipelines. Notably, this includes products that have achieved mass production and import substitution for the first time in China,” pointed out Fu Xuesen.

Notably, Mapuchi has recently succeeded in developing a micro-guidewire for neurointerventional therapy, which is expected to fill the domestic gap in intracranial treatment guidewires. Its performance can fully replace similar imported products. This neurointerventional micro-guidewire from Mapuchi Medical is composed of two metal materials, representing an innovation in synthesis technology. The guidewire offers strong support and a soft distal end, enabling access to deeper lesions and facilitating surgical procedures.

Finally, regarding future plans, Fu Xuesen stated: “In the future, we hope to continue broadening our product portfolio while expanding sales to Europe, the United States, Japan, and other regions. In the domestic market, we aim to become a Chinese-made brand capable of replacing Terumo, striving to be China’s ‘Terumo.’”

About Sanze Venture Capital

Sanze Venture Capital, established in 2008, is a council member of the Venture Capital Professional Committee of the China Investment Association and the Guangdong Venture Capital Promotion Association, as well as a founding organization and vice-presidential unit of the Hunan Equity Investment Association. It is among the first batch of professional institutions in China to qualify for fund management guided by capital injections from both national finance and local governments, and was one of the first private equity investment management firms approved by the China Securities Regulatory Commission (CSRC). Sanze Venture Capital efficiently integrates industrial and financial capital, leveraging an open organizational structure and operational mechanisms as foundational safeguards to provide personalized investment and operational value-added services to high-tech, high-growth small and medium-sized enterprises (SMEs) in China.